Development of a selective biosensor for detecting organophosphate pesticide expo

描述(由申请人提供) 这个SBIR项目是为了响应开发现场可部署或可穿戴的个人传感器的呼吁，通过生物采样测试来监测接触点对空气中化学品的暴露。这项提议的广泛目标是开发一种极其灵敏和选择性的生物传感器设备，能够检测和区分从疑似接触到潜在有害水平的有机磷农药的患者的血清样本中提取的蛋白质。这代表了生物标记物分析的一种新方法，因为每一种有机磷(OP)农药都会产生一个独特的蛋白质“指纹”结构，可以被识别、与其他试剂及其结合物区分开来，并被量化。使用ATERIS技术公司新颖的传感器薄膜聚合物薄膜技术，报告结构域将被定制为检测OP中毒蛋白质的特定蛋白质识别分子。这将使开发一种廉价、但高度快速、灵敏和准确的设备来分析OP杀虫剂的暴露，评估OP剂暴露的类型和程度，然后这些信息将指导必要的治疗干预。第一阶段SBIR项目的主要里程碑是首先分离能够区分天然和OP中毒的人类蛋白质的生物识别蛋白质，然后证明薄膜传感器元件的灵敏度和可靠性的原理证明。在该计划的第二阶段，将把检测膜整合到阅读器设备中，并将确定在实际血清样本中检测OP修饰的蛋白质的重复性和准确性。所产生的数据将指导商业生物传感器装置的设计。这种设备的最终用户将是可能接触OP杀虫剂的现场人员和可能遇到疑似接触OP化学制剂的患者的临床实验室。

DESCRIPTION (provided by applicant) This SBIR project is in response to the call for the development of field-deployable or wearable personal sensors for monitoring point-of-contact exposures to airborne chemicals through biosample testing. The broad objective of this proposal is to develop an extremely sensitive and selective biosensor device capable of detecting and discriminating proteins in human serum samples taken from patients suspected of being exposed to potentially harmful levels of organophosphate-based pesticides. This represents a novel approach in biomarker analysis because each organophosphate (OP) pesticide results in a distinct protein "fingerprint" structure that can be identified, distinguished from other agents and their conjugates, and quantified. Using ATERIS Technologies novel sensor thin polymer film technology, reporter domains will be customized with specific protein-recognition molecules that detect the OP poisoned proteins. This will make it possible to develop an inexpensive, yet highly rapid, sensitive, and accurate device to analyze exposure to OP pesticides, assess the type and extent of OP agent exposure and then this information will guide the therapeutic intervention necessary. The major milestones in this Phase I SBIR project are first to isolate biorecognition proteins capable of discriminating between native and OP-poisoned human proteins, then show proof-of-principal for the sensitivity and reliability of the film sensor element. In the Phase II of this program, the detection films will be incorporated into a reader device and the reproducibility and accuracy of detection of OP-modified proteins in actual serum samples will be determined. The data generated will guide the design of the commercial biosensor device. The end user of such a device will be the field personnel likely to be exposed to OP pesticides and clinical laboratories likely to encounter patients that are suspected to have been exposed to OP chemical agents.